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www.cdatm.orgAbstractDespite tremendous efforts to fight cancer, it remains a major public health problem and a leading cause of death worldwide.
With increased knowledge of cancer pathways and improved technological platforms, precision therapeutics that specifically target
aberrant cancer pathways have improved patient outcomes. Nevertheless, a primary cause of unsuccessful cancer therapy remains
cancer drug resistance. In this review, we summarize the broad classes of resistance to cancer therapy, particularly pharmacoki-
netics, the tumor microenvironment, and drug resistance mechanisms. Furthermore, we describe how bacterial-mediated cancer
therapy, a bygone mode of treatment, has been revitalized by synthetic biology and is uniquely suited to address the primary
resistance mechanisms that confound traditional therapies. Through genetic engineering, we discuss how bacteria can be potent
anticancer agents given their tumor targeting potential, anti-tumor activity, safety, and coordinated delivery of anti-cancer drugs.
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259A. Zargar et al. / Chronic Diseases and Translational Medicine 5 (2019) 258e266In 1971, the US government passed the National
Cancer Act, which provided more funding and support
for the nation’s effort in what colloquially became
known as the “war on cancer.” Despite the tremendous
progress made in screening, detection, and treatment,
the number of cancer deaths in the United States has
nearly doubled from 335,000 in 1971 to 600,920 in
2017.1 Chemotherapy is a widely used treatment for
cancers that have spread from the primary tumor
location. However, chemotherapeutic drug resistance is
a major impediment to patient survival and is the pri-
mary cause of patient death in most advanced stage
cancers.2 In fact, unsuccessful chemotherapeutic
treatment is often a result of multifactorial issues
dependent on pharmacokinetics, the tumor microenvi-
ronment (TME), and drug resistance.3,4 As a targeted
alternative to systemic chemotherapy, bacterial-
mediated therapy could deliver tumor clearance in
diverse and metastatic cancers. While it has been
known for at least 200 years that infections with mi-
crobes could result in cancer remission, this remained a
dormant field until recently, where advancements in
synthetic biology now enable controlled targeting and
delivery of therapeutic agents. In this review, we
discuss the challenges of traditional chemotherapeutic
treatment and advancements in bacterial-mediated
therapy that overcome these obstacles.
Pharmacokinetic failure
Therapeutic dose levels that can successfully treat a
tumor site require a satisfactory ADME (Absorption,
Distribution, Metabolism, Excretion) profile. Pharma-
cokinetic failure that results in insufficient dosing at
the tumor site can lead to incomplete antitumor therapy
resulting in residual disease (Fig. 1).5 Major sources ofFig. 1. Drug formulations with poor ADME profiles can result inpharmacokinetic failure can be due to issues with drug
solubility, distribution, and dose-limiting toxicity that
incompletely suppress the targeted tumor pathway.6
Also, tumor cells themselves can actively reduce the
intracellular drug concentration through efflux pumps
that transport anticancer drugs, thereby providing
another level of resistance.7 While mathematical
models have been developed to predict drug delivery,
drug concentration, and tumor clearance,8,9 the multi-
factorial nature of the problem makes successful tar-
geted therapy a challenge.
As such, there has been much effort in developing
therapies that are target ligand specific. While these
efforts have resulted in powerful advances in thera-
peutics, both targeted and untargeted therapies have
very low levels of accumulation of the injected dose at
the target site. Delivery of the injected dose to the
targeted cancer site can range from below 0.1% for
drugs without a targeting ligand (e.g. small molecule
inhibitors) to over 1% of the injected dose for targeted
drugs (e.g. antibody drug conjugates).10 However,
while the low percentage of the total dose can be
discouraging, the critical factor for successful treat-
ment is the ratio between on-site and off-site accu-
mulation. Increases in target site activation without an
increase in toxicity from accumulation in normal tissue
could thus greatly improve patient outcomes.
Barriers of the tumor microenvironment
While once thought of as a detached spectator to
cancer progression, the complex interplay between the
tumor and stroma is a fundamental hallmark of cancer
and is known to influence tumor progression, metas-
tasis, and importantly, therapeutic resistance.11 The
TME consists of a variety of malignant cells, stromalincomplete tumor remission leading to a refractory response.
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cytokines that can secrete into an extracellular matrix
(ECM).12 In various cancer types, the TME has been
shown to reduce drug penetration, provide proliferative
and anti-apoptotic advantages to the tumor cells, and
modify the immune response.13
A major cause of drug resistance from the tumor
microenvironment is the ECM physical barrier against
cytotoxic therapeutics (Fig. 2). The ECM is mainly
composed of glycoproteins, proteoglycans, elastin,
collagen, and hyaluronan. Increasing amounts of ECM
has been shown to have a direct impact on the intra-
tumoral drug concentration, due to reduced penetration
and distribution.14 A study on pancreatic ductal car-
cinoma has shown that excessive stroma can cause
increased tumor stiffness and compressed tumor ves-
sels resulting in decreased drug accumulation in the
tumor.15 Moreover, increased stiffness in the ECM of
hepatic carcinoma has also been shown to promote
drug resistance.16 Originating from the ECM, exo-
somes are another TME component that reduces drug
penetration by trapping therapeutic antibodies such as
rituximab and trastuzumab, thereby limiting thera-
peutic efficacy.17,18
Pharmaceuticals have been developed to specif-
ically degrade the ECM to improve therapeutic de-
livery. Increased levels of hyaluronan, a linear
polysaccharide found in the extracellular space of most
tissues, results in increased interstitial pressure and
reduced drug penetration.19 Collagen is also overex-
pressed in many tumors leading to proliferative onco-
genic environment through structural and signaling
interactions.20 As such, ECM remodeling enzymes
such as hyaluronidase and collagenase have been used
in conjunction with anticancer drugs to increase drug
penetration.21,22 However, the timing and control ofFig. 2. Tumors with an extensive extracellular matrix can result in incomp
therapy and tumor refraction.ECM degradation must be carefully controlled, as
enhanced metastasis of cancer cells due to loss of ECM
integrity can be a dangerous side effect.23
Drug resistance
While conventional cytotoxic drugs such as 5-
fluorouracil have been widely used as cancer thera-
peutics, increased knowledge of molecular cancer
mechanisms has allowed the development of precision
medications (e.g. targeted therapies such as kinase in-
hibitors). These targeted therapies disrupt the function
of oncogenic driver proteins and have revolutionized
cancer therapy. A few examples include kinase in-
hibitors of epidermal growth factor receptor (EGFR),
anaplastic lymphoma kinase (ALK), and BRAF. Unlike
conventional cytotoxic drugs that simply target rapidly
proliferative cells, these precision therapies specifically
target molecular aberrations common in cancerous
tissues, with a relatively lesser effect on normal tis-
sue.24 A canonical example is the targeting of the ki-
nase BRAF, a member of the mitogen-activated protein
(MAP) kinase signal transduction pathway responsible
for growth and cell differentiation by kinase inhibitors
such as vemurafenib.25 The basis of these precision
therapies could only be realized by the identification of
the primary genetic drivers of cancer progression
through rigorous mechanistic laboratory studies
coupled with biomarker-driven clinical trials.26
Despite the success of these treatments, many can-
cers eventually adapt to both conventional and preci-
sion pharmaceuticals, and this resistance is a primary
cause of patient death in most advanced stage cancers.2
Resistance may be present at the time of initial therapy
(intrinsic) or may develop during the course of the
therapy (acquired). Drug resistance is multifactorial,lete penetration of anticancer drugs leading to incomplete anti-tumor
Fig. 3. Tumor heterogeneity can result in subpopulations of cells with distinct molecular signatures with varying drug sensitivities. Drug-sensitive
cells can be eliminated while a drug-resistant subpopulation can cause tumor refraction.
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netic heterogeneity between and within tumor pop-
ulations that can result in subpopulations with different
drug sensitivities.4 The administration of an anticancer
drug to a mixture of drug-sensitive and drug-resistant
subpopulations in a tumor can be a significant cause
of drug resistance (Fig. 3).27 A convergence-based
classification of resistance mechanisms can illuminate
polytherapy pathways that target parallel cancer de-
pendencies. By simultaneously targeting these resis-
tance pathways, polytherapies are less likely to result
in resistance to a multi-drug mixture. Importantly, in
some cases a polytherapy is better tolerated than each
individual agent due to off-setting toxicities (e.g.
BRAF þ MEK inhibitor treatment),28 while increased
off-target toxicity in others can result in greater
toxicity with polytherapies.29
New therapeutic platforms are needed to address the
multifactorial challenges presented by drug delivery,
the TME, and tumor heterogeneity. Synthetic biology
has enabled the creation of “living therapeutics” that
are biologically programmed to perform specific pre-
designed therapeutic treatments. With the ability to
actively move towards the nutrients at the cancer site
via chemotaxis, modulate the TME, and deliver on-site
therapies, genetically modified bacteria are a prom-
ising and relatively unexplored avenue in cancer
therapeutics.
Bacterial-mediated therapy
In the late 19th century, Dr. William Coley began
experimenting with treating his cancer patients with
Streptococcus pyogenes.30 Now considered the father
of cancer immunotherapy, Coley’s toxins, as they came
to be known, were largely set aside once radiotherapywas developed. In the past few decades, however, there
has been renewed interest in both preclinical and
clinical studies in using bacteria for cancer therapy.
Bacterial-mediated therapy may be used to treat
nearly all cancer sites including blood cancer, sarcoma,
melanoma, and solid carcinomas. Oral administration
of genetically engineered probiotics is an exciting
avenue to treat gastrointestinal cancer31 and enteral
administration of heterologous bacteria, either as an
isolated probiotic or a fecal transplant, is well-studied
and has reduced safety concerns compared to paren-
teral administration.32 However, the vast majority of
clinical and preclinical trials to treat cancer has been
through direct tumor injection and intravenous sys-
temic injection of tumor-targeting bacteria, which is
the context we discuss in this review.
In principle, bacteria may be engineered to selec-
tively target a tumor site, multiply within the tumor
microenvironment, recruit the immune system, and
release multiple drugs targeting parallel disease path-
ways resulting in complete elimination of the cancer
cells (Fig. 4). With advancements in synthetic biology,
bacterial mediated therapy can be programmed to
address the shortcomings of conventional treatment in
dealing with pharmacokinetics, the tumor microenvi-
ronment, and drug resistance. We discuss the progress
made in addressing these challenges with bacterial-
mediated therapy below as well as highlight safety
and prospective directions and opportunities.
Targeting and on-site production
Bacteria have a unique ability to selectively target
and colonize tumors compared to normal tissues. Small
molecules produced by tumor cells can act as chemo-
attractants to bacteria, and the suppressed immune
Fig. 4. A genetically engineered bacterium can overcome the multifactorial challenges of drug resistance. The bacteria can actively target the
tumor site without producing the anticancer compound, reducing off-site toxicity. After reaching the tumor, the bacteria can burrow past the
extensive ECM into the hypoxic tumor core. Once the bacteria has colonized the tumor, genetic switches activated by quorum sensing or the tumor
microenvironment produce multiple therapies that target parallel disease pathways resulting in complete tumor elimination.
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ance. While an extensive ECM caused by cancer cre-
ates a hypoxic environment and reduces conventional
therapeutic dose, both obligate anaerobes (e.g. Clos-
tridium and Bifidobacterium) and facultative anaerobes
(e.g. Escherichia and Salmonella) have been shown to
colonize the necrotic and hypoxic conditions of the
tumor.33 Moreover, bacteria have been genetically
engineered to express binding peptides to selectively
target cancer biomarkers and colonize tumors
(Fig. 5).31,34 This selective colonization can be lever-
aged with other treatment modalities. Conventional
chemotherapy and radiotherapy are much more effec-
tive in the well-perfused areas compared to the more
dense, hypoxic core of a tumor where bacteria colo-
nize. The synergy of these modalities has been shown
in murine models by dosing Clostridium novyi-NTwith
radiotherapy or chemotherapeutic treatments.35,36
While precision medication can help reduce toxicity
through the targeting of aberrant molecular signatures,
its systematic delivery causes toxicity due to accumu-
lation in healthy tissues. By encoding bacteria to target
tumor sites and coordinating cellular actions throughFig. 5. Workflow of process to identify tumor targeting peptides. A library
display on the bacterial cell surface and screened against normal cells andsensing of the TME, therapeutics can be released on-
site, greatly reducing off-site toxicity. Through pro-
moters that are activated by differential pH, nutrient, or
oxygen availability, bacteria have been engineered to
the TME thereby limiting off-site delivery.37,38
Leveraging the preferential accumulation of bacteria
at the tumor site, genetic switches have been developed
that respond to bacterial cell-density dependent
quorum sensing (QS). As these bacteria accumulate at
a site, the communication molecules they produce
eventually reach a critical threshold activating the ge-
netic switch and coordinating gene expression. This
coupling of QS mechanisms to drug release enables
coordinated therapeutic release and acts as a safety
valve to prevent off-site accumulation and increase
drug delivery.39
Tumor clearance through immune system activation
and direct oncolysis
The intrinsic ability of bacterial cells to colonize the
TME can result in remodeling of the environment,
primarily through the activation of immune pathways.of known peptides that bind specific cancer receptors is engineered to
the target cancer cell line.
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ular patterns (PAMPs) such as flagella, pili, and lipo-
polysaccharide by bacteria elicit the immune system in
a manner unique to each bacterial strain. This response
includes repolarization of tumor associated macro-
phages, elimination of tumor associated myeloid
derived suppressor cells, and promotion of dendritic
cell maturation.40 A prominent example is the sensi-
tization of cluster of differentiation (CD) 8þ T cells, a
major component of the adaptive immune response, to
tumor antigens by enhancing T-cell receptor
signaling.41 Beyond the natural ability of some bacteria
to elicit immune pathways, the immune-suppressive
TME can be activated to become immune stimulating
through the release of adjuvants, antigens, cytokines
and checkpoint inhibitors.33 Salmonella enterica and
C. novyi-NT have been engineered to release cytokines
or tumor-specific antigens to convert the TME from
immune-suppressive to immune-activated.42 Exciting
new studies in Escherichia coli have shown that a lysis
mechanism based on quorum sensing can be used to
release nanobody fragments against receptors pro-
grammed death ligand-1 (PD-L1), cytotoxic T
lymphocyte associated antigen-4 (CTLA-4) and CD47,
thereby reducing or clearing tumor growth in synge-
neic mouse models.43,44
Beyond bacterial recruitment of immune cells,
genetically engineered bacteria can directly cause
tumor regression by competing for nutrients, uncon-
trolled growth that causes tumor cells to lyse, or
through secretion of exotoxins and pro-apoptotic
molecules.45 In syngeneic mice models, the direct
release of a clinical therapeutic along with an exotoxin
haemolysin E, a pore-forming anti-tumor toxin, by
genetically engineered E. coli, resulted in reduced
tumor activity in a syngeneic mouse transplantation
model with metastatic hepatic carcinoma.46
Systemic cytokines stimulate the immune system
and directly cause preferential apoptosis of cancer cells
compared to normal healthy cells. However, systemic
cytokine injection cannot be used due to off-target
toxicity, whereas localized release by bacteria could
reduce tumor size without causing widespread toxicity.
Such release of pro-apoptotic cytokines by genetically
engineered bacteria has already begun to be explored,
including the expression of FAS-ligand, tumor necrosis
factor alpha (TNF-a), and TNF-related apoptosis-
inducing ligand.47e49
A therapeutic platform that enables more selective
on-target drug release of multiple therapies that act in
parallel would represent a significant step in cancer
therapeutics. Systemic administration of drug cocktailsthat target multiple disease pathways can have
dangerous side effects. By genetically encoding the
localized production of anti-tumor compounds, targeted
bacteria could, in principle, selectively release multiple
oncolytic therapeutics. Moreover, programmable design
through genetic circuits could enable controllable timed
release of therapeutics for maximum efficiency. While
most bacteria have been engineered to release simple
peptides, many chemotherapeutics are inspired or
directly taken from natural products. Through heterol-
ogous natural product synthesis, bacteria could be
engineered to release Food and Drug Administration
(FDA)-approved chemotherapeutics.
Safety of bacterial-mediated therapy
Numerous preclinical pharmacological and toxicity
studies have shown that select bacteria have satisfac-
tory safety profiles in healthy and tumor bearing ani-
mals.50,51 The FDA has approved several clinical trials
with tumor targeting bacteria.52e54 These studies
showed acceptable safety profiles with promising re-
sults for anti-tumor activity. The most noteworthy
clinical example is the FDA-approved treatment of
bladder cancer with the Bacillus Calmette-Guerin
vaccine, an attenuated Mycobacterium bovis.55
In the studies shown so far, substantial colonization
has been required for clinical benefit, which highlights
the uniqueness of the dose profile with a live thera-
peutic. As live bacteria generally multiply in the tumor
site, the injected dose of bacteria plays less of a role
than the type of tumor and bacterium used. Well-
perfused tumors compared to necrotic tumors will
have different colonization profiles depending on the
type of bacterium employed. Genetic circuits pro-
grammed to maintain bacterial density at a certain
threshold have been developed.46 If these systems were
applied to a tumor site, a density-dependent signal
would trigger a kill switch in a subset of the popula-
tion, thereby maintain a bacterial density range
(Fig. 6). With the maturation of synthetic biology en-
hancements allowing the precise delivery of oncolytic
payloads, future Phase I clinical trials may reveal that
lower bacterial loads are required for successful anti-
tumor activity.
Future directions
With its anti-tumor effects and preference to selec-
tively colonize tumors, bacterial-mediated therapy has
the potential to treat cancers that are resistant to current
therapies, including refractory metastatic cancer and
Fig. 6. Control mechanisms to maintain bacterial population. Ge-
netic circuits have been created to maintain bacterial population in
microfluidic devices. Adapted to colonization of cancer sites, initial
colonization would contain few cells and signaling molecules (left-
most bubble). Cell growth reaches a critical threshold and the
signaling molecule causes lysis in a subset of the population, which
then undergoes growth again until the threshold is reached again.
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and tissue target, bacterial-mediated therapy could be
effective beyond direct treatment of manifested cancer.
By targeting precancerous lesions, microbes could be
engineered to prevent tumor occurrence or recurrence.
While there is great potential in bacterial-mediated
therapy, improved tools and knowledge are required
for successful clinical translation.
Synthetic biology advancements have enabled bac-
teria to perform more coordinated and complex ac-
tions, which is a major advantage to their use as a
“living therapeutic”. While most synthetic biology
studies have centered on well-studied organisms,
particularly E. coli, the recent genetic “domestication”
of a wide variety of organisms could provide a better-
suited chassis for applications such as anticancer
therapy. The bacteria studied the most in this context
have been E. coli, Salmonella typhimurium, and S.
enterica because of their relative ease of genetic
manipulation. Future efforts should develop genetic
tools in other non-model organisms that naturally elicit
the immune system, but were previously considered
too difficult to engineer, such as Listeria mono-
cytogenes and C. novyi.
An important therapeutic consideration is the level and
timing of therapeutic dose. As tumor heterogeneity can
contain a drug-insensitive population that can flourish ifthe drug-sensitive population is eliminated, intermittent
dose programs to contain the tumor at a certain size could
be the preferred course.56 Further, drug discontinuation
can also result in the re-sensitization of tumor cells to the
drug.Genetic circuits have beenbuilt inE. coli to oscillate
cell population with varying growth dynamics within the
TME.46 These forms of circuits could be used to not only
maintain the bacterial population, but also oscillate ther-
apeutic releasewithout subsequent injecteddoses (Fig. 6).
Advancements in cancer treatment require an
increased understanding of cancer pathogenesis, partic-
ularly as the cancer evolves. In fact, under-sampling of
cancers has been noted as a critical knowledge gap in
tumor progression.2 To help provide some of this infor-
mation, tools such as liquid biopsies have been developed
that monitor genetic, transcriptional and epigenetic
changes by isolating circulating tumor cells from the
blood.57A promisingmethod to further understand tumor
development could be through colonized bacteria. For
example, bacteria have been engineered to sense and re-
cord changes in their environment through targeted al-
terations in their own DNA.58,59 Applying these bacteria
that record changes in tumor cells or tumor microenvi-
ronments in real time could provide vital information
about cancer progression and regression.Conflicts of interest
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